Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling

Fig. 1

CD27CD10 tonsillar B cells express CD22 and internalize Emab. a, b Characterization of tonsillar B-cell subsets. Tonsillar cells were stained with fluorochrome-labeled mAbs against CD10, CD19, CD22, CD27, CD38, and IgD and analyzed using multicolor flow cytometry. a Representative flow analysis of gated live CD19+ cells showing B-cell subgating into CD10CD27, CD10CD27+, and CD10+CD27+/– subsets; right histograms show expression of CD38 and IgD within each population. b Surface expression of CD22 quantified by flow cytometry and compared to corresponding B-cell subsets from PBMCs of healthy donors. Each dot on the graph represents individual donors. c Tonsillar B cells were stained with mAb specific for CD10, CD27, and CD20 (green) and with Emab, conjugated to Pacific Blue (purple). Cells were incubated at 4 or 37 °C, and Emab surface binding and internalization of CD10CD27 cells was visualized by imaging flow cytometry. Data shown are representative of three independent experiments. Emab epratuzumab, PBMC peripheral blood mononuclear cell

Back to article page